拜卡林通过诱导代谢重编程和向腺素A1受体来缓解脂肪细胞中的脂质积累
Zaikuan Zhang1, Runzhi Wang2, Jin Cai2
1The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, PR China.
概括
拜卡林通过重编程脂肪细胞来减少脂质储存来对抗肥胖. 它通过糖解和脂肪酸氧化增强能量生产,向腺氨酸A1受体 (ADORA1) 抑制脂质合成.
科学领域:
- 生物化学 生化学
- 代谢研究的研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 过度的脂质积累导致肥胖和代谢疾病,如脂肪肝和2型糖尿病.
- 目前用于细胞内脂质积累的治疗方法缺乏有效性和安全性.
- 巴伊卡林正在研究其减轻这些疾病的潜力.
研究的目的:
- 研究贝卡林对细胞代谢和脂肪细胞中的脂质积累的影响.
- 为了确定受贝卡林处理影响的分子点和途径.
- 评估贝卡林对肥胖和相关代谢障碍的治疗潜力.
主要方法:
- 细胞呼吸试验 (氧气消耗,糖解流).
- 基因和蛋白质表达分析 (Cd36,Fabp4,FASN).
- 转录组分析,分子对接和通路丰富分析.
主要成果:
- 贝卡林降低了线粒体的氧气消耗,增加了糖分的流量,改变了细胞的能量生产.
- 它通过降低关键的脂质储存基因来降低脂质滴和甘油三水平.
- 贝卡林高调糖解和脂肪酸氧化 (FAO),同时降调酸脱酶,准ADORA1,以抑制SREBP1成熟和脂质生物合成.
结论:
- 贝卡林诱导脂肪细胞中的代谢重编程,将能量生产转向糖解和粮农组织.
- 它针对ADORA1,抑制SREBP1处理并减少脂质合成.
- 贝卡林作为治疗肥胖症和相关代谢疾病的治疗剂具有前景.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
393
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
393
Adrenergic Receptors: β Subtype
1.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
504
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
504
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
769
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
769
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
514
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
514
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
475
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
475


